Compare Tango Therapeutics Inc. (TNGX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Consumer Staples Select Sector SPDR Fund — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Consumer Staples Select Sector SPDR Fund trades at $87.29 (market cap $14.73B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 3.9× Tango Therapeutics Inc.'s market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Consumer Staples Select Sector SPDR Fund for 73 Days on average.
| TNGX | XLP | |
|---|---|---|
Market Cap | $3.74B | $14.73B |
Volume | 3,438,781 | 14,288,954 |
Sector | Health | — |
52-Week High | $32.90 | $90.00 |
52-Week Low | $7.50 | $75.61 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
XLP trades at $84.19, down 0.26% on the day, with a bullish technical outlook supported by moving averages and ADX signals. Analyst consensus is unanimously positive with 100% buy ratings. Recent news highlights its competitive expense ratio and defensive appeal amid market volatility, with strong performance relative to discretionary sectors in 2026.
The ETF's low costs and sector resilience underpin a favorable outlook, though overbought RSI levels and interest rate sensitivity pose near-term risks. Institutional favor and dividend stability offer long-term value, but macroeconomic pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
